A Phase 2 interventional study of Collagenase clostridium histolyticum and Placebo in Dupuytren's Disease, sponsored by Endo Pharmaceuticals. Completed at 11 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-10-05.
Sponsored by Endo Pharmaceuticals (part of Keenova Therapeutics plc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing Microbial Collagenase in Dupuytren Contracture — none open to participants now, 1 under way, none of them phase 3. Microbial Collagenase · Dupuytren Contracture.
Among the 17 studies testing Microbial Collagenase in Dupuytren Contracture, this one is the 9th largest by enrollment, is the only one that started in 2014, is the only one in phase 2, and was the 13th registered.
78 studies on the registry are indexed under Dupuytren Contracture; 18 are open to participants now.
Browse Dupuytren Contracture studies →None of the 17 studies testing Microbial Collagenase in Dupuytren Contracture is open now. The open studies under Dupuytren Contracture, anywhere →
Microbial Collagenase: first FDA approval 1965 (SANTYL), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 12 Dupuytren Contracture studies recruiting now, 10 (83%) set no upper age limit and 1 (8%) stops at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2014.
This study's enrollment of 76 is close to the median of 72 across 57 interventional studies indexed under Dupuytren Contracture.
Median enrollment 76 across the 17 interventional studies. Of the 15 that completed or were terminated, 12 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 17 have an industry lead sponsor. The 10 most frequent:
This study is registered under Endo Pharmaceuticals, one of the names counted as Keenova Therapeutics plc. Under that name alone:
Endo Pharmaceuticals is the lead sponsor of 99 studies on the registry; none are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 14 (88%) have results posted.
10 studies in Dupuytren Contracture by Keenova Therapeutics plc: none open now, none under way, none of them phase 3. Of 10 finished, 6 (60%) have results posted.
Among the 10 studies in Dupuytren Contracture by Keenova Therapeutics plc, this one is the only one that started in 2014, is the only one in phase 2, and was the 9th registered.
Keenova Therapeutics plc’s Dupuytren Contracture studies by the year they started, since 2007.
None of the studies under way reaches primary completion within a year.
Among the 17 studies testing Microbial Collagenase in Dupuytren Contracture, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Keenova Therapeutics plc’s 10 in Dupuytren Contracture:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objectives of this study are to assess the safety and effectiveness of AA4500 in treating palmar Dupuytren's disease nodules.
Approximately 13 sites in the United States and Australia, approximately 90 study subjects.
After all pre-injection procedures are completed on day 1, eligible men and women will be randomized in a 1:1:1 ratio to dose group and then in a 4:1 ratio to treatment group. Study drug will be administered into a palmar nodule located on the selected hand.
AA4500 (collagenase clostridium histolyticum) 3 doses (low, medium, and high) after reconstitution with sterile diluent (0.3 mg/mL calcium chloride dihydrate in 0.9% sodium chloride). Each dose of study drug will be injected into the nodule. The injection will be administered in 3 different volumes according to randomization.
Placebo after reconstitution with sterile diluent (0.3 mg/mL calcium chloride dihydrate in 0.9% sodium chloride). Each dose of study drug will be injected into the nodule. The injection will be administered in 3 different volumes according to randomization.
Follow up visits for the evaluation of safety and efficacy will be required for all subjects on days 8, 29, and 57.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Have a diagnosis of Dupuytren's disease AND have at least one palmar nodule on the selected hand that is:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Collagenase clostridium histolyticum, single 0.25 mg injection
Biological: Collagenase clostridium histolyticum
Collagenase clostridium histolyticum, single 0.40 mg injection
Biological: Collagenase clostridium histolyticum
Collagenase clostridium histolyticum, single 0.60 mg injection
Biological: Collagenase clostridium histolyticum
Placebo, single 0.25 mg, 0.40 mg, or 0.60 mg injection
Biological: Placebo
Single injection into nodule
Also known as: AA4500, XIAFLEX, XIAPEX
Single injection into nodule
Percent Change From Baseline in Surface Area and Volume of the Treated Nodule at Day 57 Using Caliper Measurements
Percent change from baseline in surface area and volume of the treated nodule was determined from hand-held caliper measurements of the length and width of the nodule. Percent change = 100\*(Day 57 area \[or volume\] - baseline area \[or volume\])/baseline area \[or volume\]. A negative value represents the improvement from baseline (decreased size) while a positive value represents worsening.
Time frame: Baseline, Day 57
Percent Change From Baseline in Surface Area and Volume of the Treated Nodule at Day 57 Using Ultrasound
Percent change from baseline in surface area and volume of the treated nodule was determined from ultrasound measurements of the length, width, and depth of the nodule. Percent change = 100\*(Day 57 area \[or volume\] - baseline area \[or volume\])/baseline area \[or volume\]. A negative value represents the improvement from baseline (decreased size) while a positive value represents worsening.
Time frame: Baseline, Day 57
Change From Baseline in Consistency of the Treated Nodules at Day 57
Investigators determined the consistency of the nodule through palpitation using a 5-point scale: 5 = hard (solid), 4 = firm throughout, 3 = moderate firmness, 2 = soft, and 1 = non-palpable. The change scores could range from +4 (greatest worsening in consistency) to -4 (greatest improvement in consistency); a negative change from baseline value reflects improvement from baseline (softening) while a positive value reflects worsening.
Time frame: Baseline, Day 57
Percent Change From Baseline in Hardness of the Treated Nodule at Day 57
A durometer was used to assess nodule hardness on a scale of 0 (soft) to 100 (hard). Percent change = 100\*(Day 57 hardness - baseline hardness)/baseline hardness. A negative value represents the improvement from baseline (softening) while a positive value represents worsening.
Time frame: Baseline, Day 57
Change From Baseline in Nodular Pain of the Treated Nodule at Day 57
After the nodule was squeezed using a dynamometer, subjects were asked to rate the amount of pain they felt on an 11-point visual analog scale (VAS) from 0 (no pain or discomfort) to 10 (extreme pain or discomfort). A negative change from baseline value reflects improvement from baseline (less pain) while a positive value reflects worsening.
Time frame: Baseline, Day 57
Investigator Global Assessment of Improvement With Treatment
Investigators were asked to determine the degree of improvement in the subject's treated nodule compared with screening on a 7-point scale: 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse.
Time frame: Day 57
Subject Satisfaction With Treatment
Subjects were asked to rate their satisfaction with treatment on a 5-point scale: 1 = very satisfied, 2 = quite satisfied, 3 = neither satisfied nor dissatisfied, 4 = quite dissatisfied, and 5 = very dissatisfied.
Time frame: Day 57
Composite Responder Analysis
A composite responder is a subject who had an improved assessment \[values of 1 (very much improved), 2 (much improved), or 3 (minimally improved)\] on the investigator global assessment and had a satisfied assessment \[values of 1 (very satisfied) or 2 (quite satisfied)\] on the subject assessment.
Time frame: Day 57
| Milestone | AA4500 0.60 mg | AA4500 0.40 mg | AA4500 0.25 mg | Placebo |
|---|---|---|---|---|
| Started | 18 | 18 | 23 | 17 |
| Completed | 18 | 18 | 22 | 16 |
| Not completed | 0 | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 1 |
Percent change from baseline in surface area and volume of the treated nodule was determined from hand-held caliper measurements of the length and width of the nodule. Percent change = 100\*(Day 57 area \[or volume\] - baseline area \[or volume\])/baseline area \[or volume\]. A negative value represents the improvement from baseline (decreased size) while a positive value represents worsening.
| percentage of change | AA4500 0.60 mg | AA4500 0.40 mg | AA4500 0.25 mg | Placebo |
|---|---|---|---|---|
| Surface Area | -81.61 ± 20.251 | -80.11 ± 21.459 | -58.30 ± 29.849 | -41.76 ± 32.445 |
| Volume | -89.03 ± 15.016 | -87.58 ± 16.372 | -68.15 ± 33.859 | -49.13 ± 36.736 |
Percent change from baseline in surface area and volume of the treated nodule was determined from ultrasound measurements of the length, width, and depth of the nodule. Percent change = 100\*(Day 57 area \[or volume\] - baseline area \[or volume\])/baseline area \[or volume\]. A negative value represents the improvement from baseline (decreased size) while a positive value represents worsening.
| percentage of change | AA4500 0.60 mg | AA4500 0.40 mg | AA4500 0.25 mg | Placebo |
|---|---|---|---|---|
| Surface Area | -34.23 ± 41.353 | -19.37 ± 39.658 | -10.30 ± 41.696 | -4.54 ± 54.784 |
| Volume | -40.99 ± 46.612 | -13.01 ± 68.804 | -9.52 ± 60.156 | -7.19 ± 69.877 |
Investigators determined the consistency of the nodule through palpitation using a 5-point scale: 5 = hard (solid), 4 = firm throughout, 3 = moderate firmness, 2 = soft, and 1 = non-palpable. The change scores could range from +4 (greatest worsening in consistency) to -4 (greatest improvement in consistency); a negative change from baseline value reflects improvement from baseline (softening) while a positive value reflects worsening.
| units on a scale | AA4500 0.60 mg | AA4500 0.40 mg | AA4500 0.25 mg | Placebo |
|---|---|---|---|---|
| Change From Baseline in Consistency of the Treated Nodules at Day 57 | -1.9 ± 0.93 | -1.9 ± 1.05 | -1.2 ± 1.10 | -0.3 ± 0.96 |
A durometer was used to assess nodule hardness on a scale of 0 (soft) to 100 (hard). Percent change = 100\*(Day 57 hardness - baseline hardness)/baseline hardness. A negative value represents the improvement from baseline (softening) while a positive value represents worsening.
| percentage of change | AA4500 0.60 mg | AA4500 0.40 mg | AA4500 0.25 mg | Placebo |
|---|---|---|---|---|
| Percent Change From Baseline in Hardness of the Treated Nodule at Day 57 | -17.05 ± 15.584 | -30.40 ± 24.930 | -17.87 ± 22.265 | 4.80 ± 23.959 |
After the nodule was squeezed using a dynamometer, subjects were asked to rate the amount of pain they felt on an 11-point visual analog scale (VAS) from 0 (no pain or discomfort) to 10 (extreme pain or discomfort). A negative change from baseline value reflects improvement from baseline (less pain) while a positive value reflects worsening.
| units on a scale | AA4500 0.60 mg | AA4500 0.40 mg | AA4500 0.25 mg | Placebo |
|---|---|---|---|---|
| Change From Baseline in Nodular Pain of the Treated Nodule at Day 57 | -0.8 ± 1.97 | -1.6 ± 2.21 | -1.7 ± 2.57 | -0.5 ± 1.77 |
Investigators were asked to determine the degree of improvement in the subject's treated nodule compared with screening on a 7-point scale: 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse.
| units on a scale | AA4500 0.60 mg | AA4500 0.40 mg | AA4500 0.25 mg | Placebo |
|---|---|---|---|---|
| Investigator Global Assessment of Improvement With Treatment | 1.7 ± 0.84 | 1.7 ± 0.75 | 2.5 ± 1.10 | 3.0 ± 1.15 |
Subjects were asked to rate their satisfaction with treatment on a 5-point scale: 1 = very satisfied, 2 = quite satisfied, 3 = neither satisfied nor dissatisfied, 4 = quite dissatisfied, and 5 = very dissatisfied.
| units on a scale | AA4500 0.60 mg | AA4500 0.40 mg | AA4500 0.25 mg | Placebo |
|---|---|---|---|---|
| Subject Satisfaction With Treatment | 1.5 ± 0.79 | 1.6 ± 0.85 | 2.3 ± 1.17 | 2.8 ± 1.34 |
A composite responder is a subject who had an improved assessment \[values of 1 (very much improved), 2 (much improved), or 3 (minimally improved)\] on the investigator global assessment and had a satisfied assessment \[values of 1 (very satisfied) or 2 (quite satisfied)\] on the subject assessment.
| participants | AA4500 0.60 mg | AA4500 0.40 mg | AA4500 0.25 mg | Placebo |
|---|---|---|---|---|
| Responder: Yes | 14 | 16 | 12 | 6 |
| Responder: No | 4 | 2 | 10 | 10 |
Collected over Adverse events were collected from enrollment through the end of the study (Day 57).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AA4500 0.60 mg | — | 0/18 (0%) | 17/18 (94.4%) |
| AA4500 0.40 mg | — | 0/18 (0%) | 18/18 (100%) |
| AA4500 0.25 mg | — | 0/22 (0%) | 21/22 (95.5%) |
| Placebo | — | 0/17 (0%) | 7/17 (41.2%) |
| Event | AA4500 0.60 mg | AA4500 0.40 mg | AA4500 0.25 mg | Placebo |
|---|---|---|---|---|
| ContusionInjury, poisoning and procedural complications | 9/18 | 9/18 | 13/22 | 1/17 |
| Local swellingGeneral disorders | 10/18 | 7/18 | 8/22 | 3/17 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 7/18 | 10/18 | 10/22 | 1/17 |
| Injection site bruisingGeneral disorders | 6/18 | 4/18 | 5/22 | 0/17 |
| Axillary painGeneral disorders | 4/18 | 1/18 | 6/22 | 0/17 |
| Injection site swellingGeneral disorders | 0/18 | 4/18 | 5/22 | 0/17 |
| Injection site painGeneral disorders | 2/18 | 4/18 | 4/22 | 0/17 |
| Injection site pruritusGeneral disorders | 2/18 | 3/18 | 2/22 | 1/17 |
| Injection site oedemaGeneral disorders | 2/18 | 0/18 | 2/22 | 0/17 |
| PruritusSkin and subcutaneous tissue disorders | 1/18 | 2/18 | 2/22 | 0/17 |
Analysis based on Safety population; all randomized subjects who received an injection of study medication. One subject did not receive study medication.
| Age, Categorical(Participants) | AA4500 0.60 mg | AA4500 0.40 mg | AA4500 0.25 mg | Placebo | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 13 | 12 | 16 | 11 | 52 |
| >=65 years | 5 | 6 | 6 | 6 | 23 |
| Age, Continuous(years) | AA4500 0.60 mg | AA4500 0.40 mg | AA4500 0.25 mg | Placebo | Total |
|---|---|---|---|---|---|
| Median | 62.0 (41 to 84) | 60.0 (37 to 75) | 57.0 (32 to 73) | 58.0 (45 to 73) | 58.0 (32 to 84) |
| Sex: Female, Male(Participants) | AA4500 0.60 mg | AA4500 0.40 mg | AA4500 0.25 mg | Placebo | Total |
|---|---|---|---|---|---|
| Female | 6 | 10 | 11 | 7 | 34 |
| Male | 12 | 8 | 11 | 10 | 41 |
| Ethnicity (NIH/OMB)(Participants) | AA4500 0.60 mg | AA4500 0.40 mg | AA4500 0.25 mg | Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 1 | 1 | 4 |
| Not Hispanic or Latino | 17 | 17 | 21 | 16 | 71 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | AA4500 0.60 mg | AA4500 0.40 mg | AA4500 0.25 mg | Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 0 | 1 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 18 | 17 | 22 | 17 | 74 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | AA4500 0.60 mg | AA4500 0.40 mg | AA4500 0.25 mg | Placebo | Total |
|---|---|---|---|---|---|
| United States | 12 | 10 | 14 | 12 | 48 |
| Australia | 6 | 8 | 8 | 5 | 27 |
The record gives a start of Jul 2014, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2015, 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Microbial Collagenase